Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma
Nivolumab plus ipilimumab represents an effective combination of checkpoint inhibitors that can lead to a durable response with minimal toxicity in patients with metastatic renal cell carcinoma (mRCC). We present a case of a pathologic complete response to neoadjuvant nivolumab plus ipilimumab in a...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Case Reports in Urology |
| Online Access: | http://dx.doi.org/10.1155/2020/8846135 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550409975103488 |
|---|---|
| author | Taylor C. Peak Elena M. Fenu Michael B. Rothberg Christopher Y. Thomas Ronald L. Davis Edward A. Levine |
| author_facet | Taylor C. Peak Elena M. Fenu Michael B. Rothberg Christopher Y. Thomas Ronald L. Davis Edward A. Levine |
| author_sort | Taylor C. Peak |
| collection | DOAJ |
| description | Nivolumab plus ipilimumab represents an effective combination of checkpoint inhibitors that can lead to a durable response with minimal toxicity in patients with metastatic renal cell carcinoma (mRCC). We present a case of a pathologic complete response to neoadjuvant nivolumab plus ipilimumab in a patient with a 13.9 cm left renal mass and significant retroperitoneal and iliac lymphadenopathy, classified as intermediate-risk mRCC. We discuss and review the literature on complete responses after systemic therapy and the ability to predict who has undergone a complete response in the face of residual radiographic evidence of disease. |
| format | Article |
| id | doaj-art-3c5e560514ea4ba0b0ab5d50a2ebab91 |
| institution | Kabale University |
| issn | 2090-696X 2090-6978 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Urology |
| spelling | doaj-art-3c5e560514ea4ba0b0ab5d50a2ebab912025-02-03T06:06:46ZengWileyCase Reports in Urology2090-696X2090-69782020-01-01202010.1155/2020/88461358846135Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell CarcinomaTaylor C. Peak0Elena M. Fenu1Michael B. Rothberg2Christopher Y. Thomas3Ronald L. Davis4Edward A. Levine5Department of Urology, Wake Forest Baptist Medical Center, Winston-Salem, NC, USADepartment of Pathology, Wake Forest Baptist Medical Center, Winston-Salem NC, USADepartment of Urology, Wake Forest Baptist Medical Center, Winston-Salem, NC, USADepartment of Medical Oncology and Hematology, Wake Forest Baptist Medical Center, Winston-Salem NC, USADepartment of Urology, Wake Forest Baptist Medical Center, Winston-Salem, NC, USASurgical Oncology Service, Department of General Surgery, Wake Forest Baptist Medical Center, Winston-Salem, NC, USANivolumab plus ipilimumab represents an effective combination of checkpoint inhibitors that can lead to a durable response with minimal toxicity in patients with metastatic renal cell carcinoma (mRCC). We present a case of a pathologic complete response to neoadjuvant nivolumab plus ipilimumab in a patient with a 13.9 cm left renal mass and significant retroperitoneal and iliac lymphadenopathy, classified as intermediate-risk mRCC. We discuss and review the literature on complete responses after systemic therapy and the ability to predict who has undergone a complete response in the face of residual radiographic evidence of disease.http://dx.doi.org/10.1155/2020/8846135 |
| spellingShingle | Taylor C. Peak Elena M. Fenu Michael B. Rothberg Christopher Y. Thomas Ronald L. Davis Edward A. Levine Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma Case Reports in Urology |
| title | Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma |
| title_full | Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma |
| title_fullStr | Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma |
| title_full_unstemmed | Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma |
| title_short | Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma |
| title_sort | pathologic complete response to neoadjuvant nivolumab ipilimumab in a patient with metastatic renal cell carcinoma |
| url | http://dx.doi.org/10.1155/2020/8846135 |
| work_keys_str_mv | AT taylorcpeak pathologiccompleteresponsetoneoadjuvantnivolumabipilimumabinapatientwithmetastaticrenalcellcarcinoma AT elenamfenu pathologiccompleteresponsetoneoadjuvantnivolumabipilimumabinapatientwithmetastaticrenalcellcarcinoma AT michaelbrothberg pathologiccompleteresponsetoneoadjuvantnivolumabipilimumabinapatientwithmetastaticrenalcellcarcinoma AT christopherythomas pathologiccompleteresponsetoneoadjuvantnivolumabipilimumabinapatientwithmetastaticrenalcellcarcinoma AT ronaldldavis pathologiccompleteresponsetoneoadjuvantnivolumabipilimumabinapatientwithmetastaticrenalcellcarcinoma AT edwardalevine pathologiccompleteresponsetoneoadjuvantnivolumabipilimumabinapatientwithmetastaticrenalcellcarcinoma |